ETERNAL short for Extending the time window for Tenecteplase by Effective Reperfusion of peNumbrAL tissue in patients with Large Vessel Occlusion. The primary objective of ETERNAL is to test the hypothesis that thrombolytic tenecteplase (TNK, 0.25mg/kg) administered within 24 hours after symptom onset, is superior to current best practice (alteplase, tPA, 0.9mg/kg or standard care/no lysis) in achieving excellent functional outcome or return to the premorbid modified Rankin Scale at 90 days in acute ischemic stroke patients with a large vessel occlusion and a significant volume of penumbral tissue on multimodal CT or MRI.
For support please contact the study coordinator Amy MacDonald by telephone on +61 3 9342 4424 or email: firstname.lastname@example.org
The ETERNAL website and database is hosted by Apollo Medical Imaging Technology Pty Ltd on behalf of UNSRP and the Steering Committee. For technical support, please contact email@example.com